Pub Date : 2024-12-19DOI: 10.1016/s1470-2045(24)00726-5
Karl Gruber
No Abstract
{"title":"Pesticide exposure and increased risk of breast cancer for women in rural Brazil","authors":"Karl Gruber","doi":"10.1016/s1470-2045(24)00726-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00726-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"105 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142857683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-18DOI: 10.1016/s1470-2045(24)00522-9
Raffaella Casolino, Richard Sullivan, Kiran Jobanputra, May Abdel-Wahab, Miljana Grbic, Nazik Hammad, Tezer Kutluk, Nelya Melnitchouk, Alexandra Mueller, Roberta Ortiz, Diana Paez, Omar Shamieh, Gevorg Tamamyan, Horia Vulpe, Bente Mikkelsen, Andrè Ilbawi, Slim Slama
More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial effect on populations, cancer care remains underprioritised in emergency preparedness and response frameworks and humanitarian operational planning. This Policy Review summarises the perspectives and actionable recommendations from the First Global High-Level Technical Meeting on Non-communicable Diseases in Humanitarian Settings, with a focus on cancer. The paper highlights the challenges of providing cancer care in fragile, conflict-affected, and vulnerable settings and proposes a comprehensive roadmap to address both immediate and long-term needs of patients with cancer living in these settings. Key solutions include: integrating the cancer care continuum into national preparedness and response plans to enhance health-care system resilience; integrating cancer into humanitarian responses efforts; addressing the specific needs of paediatric patients with cancer; improving cancer intelligence and surveillance systems; and developing strategies to navigate the logistical and financial challenges of providing cancer care during crises. Additionally, the paper outlines practical actions and next steps for international cooperation needed to drive a shift in global health priorities and elevate cancer in the global health security agenda. We hope the presented notions will help prevent millions of avoidable deaths among people with cancer.
{"title":"Integrating cancer into crisis: a global vision for action from WHO and partners","authors":"Raffaella Casolino, Richard Sullivan, Kiran Jobanputra, May Abdel-Wahab, Miljana Grbic, Nazik Hammad, Tezer Kutluk, Nelya Melnitchouk, Alexandra Mueller, Roberta Ortiz, Diana Paez, Omar Shamieh, Gevorg Tamamyan, Horia Vulpe, Bente Mikkelsen, Andrè Ilbawi, Slim Slama","doi":"10.1016/s1470-2045(24)00522-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00522-9","url":null,"abstract":"More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial effect on populations, cancer care remains underprioritised in emergency preparedness and response frameworks and humanitarian operational planning. This Policy Review summarises the perspectives and actionable recommendations from the First Global High-Level Technical Meeting on Non-communicable Diseases in Humanitarian Settings, with a focus on cancer. The paper highlights the challenges of providing cancer care in fragile, conflict-affected, and vulnerable settings and proposes a comprehensive roadmap to address both immediate and long-term needs of patients with cancer living in these settings. Key solutions include: integrating the cancer care continuum into national preparedness and response plans to enhance health-care system resilience; integrating cancer into humanitarian responses efforts; addressing the specific needs of paediatric patients with cancer; improving cancer intelligence and surveillance systems; and developing strategies to navigate the logistical and financial challenges of providing cancer care during crises. Additionally, the paper outlines practical actions and next steps for international cooperation needed to drive a shift in global health priorities and elevate cancer in the global health security agenda. We hope the presented notions will help prevent millions of avoidable deaths among people with cancer.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"201 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142849168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-18DOI: 10.1016/s1470-2045(24)00725-3
Gruber K. Prior authorisation is can harm patients with cancer in the USA. Lancet Oncol 2024; published online Dec 12. https://doi.org/10.1016/S1470-2045(24)00719-8—In this News story, there was a typographical error in the title. This correction has been made to the online version as of Dec 18, 2024, and will be made to the printed version.
{"title":"Correction to Lancet Oncol 2024; published online Dec 12. https://doi.org/10.1016/S1470-2045(24)00719-8","authors":"","doi":"10.1016/s1470-2045(24)00725-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00725-3","url":null,"abstract":"<em>Gruber K. Prior authorisation is can harm patients with cancer in the USA.</em> Lancet Oncol <em>2024; published online Dec 12</em>. <span><span><em>https://doi.org/10.1016/S1470-2045(24)00719-8</em></span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>—In this News story, there was a typographical error in the title. This correction has been made to the online version as of Dec 18, 2024, and will be made to the printed version.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-16DOI: 10.1016/s1470-2045(24)00640-5
Logine Negm, Jiil Chung, Liana Nobre, Julie Bennett, Nicholas R Fernandez, Nuno Miguel Nunes, Zhihui Amy Liu, Martin Komosa, Melyssa Aronson, Cindy Zhang, Lucie Stengs, Vanessa Bianchi, Melissa Edwards, Sheradan Doherty, Ayse Bahar Ercan, Maria F Cardenas, Michael Macias, Matthew R Lueder, Michelle Ku, Monique Johnson, Uri Tabori
<h3>Background</h3>Gliomas are a major cause of cancer-related death among children, adolescents, and young adults (age 0–40 years). Primary mismatch repair deficiency (MMRD) is a pan-cancer mechanism with unique biology and therapeutic opportunities. We aimed to determine the extent and impact of primary MMRD in gliomas among children, adolescents, and young adults.<h3>Methods</h3>Clinical and molecular data were collected from a population-based cohort of children, adolescents, and young adults with gliomas from Toronto (TOR-Ped, age 0–18 years, collected Jan 1, 2000, to Dec 31, 2021; and TOR-AYA, age 18–40 years, collected Jan 1, 2000, to June 30, 2019). Additional validation paediatric cohorts from St Jude Children's Research Hospital (0–18 years, 2015–21) and the Children's Brain Tumor Network (0–18 years, 1981–2021) were used. Functional genomic tools were applied with the primary aim of assessing primary MMRD prevalence among glioma subgroups and germline impact. To evaluate the effect of primary MMRD on therapy and overall survival, Kaplan–Meier estimates were used on an additional cohort of patients with primary MMRD gliomas treated with immunotherapy.<h3>Findings</h3>1389 gliomas were included in the study. The prevalence of primary MMRD ranged between 3·7% and 12·4% in high-grade gliomas (overall 30 of 483; 6·2%, 95% CI 4·2–8·7) and less than 1% in low-grade gliomas (four of 899; 0·4%, 0·1–1·1; p<0·0001 by χ<sup>2</sup> test). Specific molecular analysis for all gliomas showed that primary MMRD was absent among oligodendrogliomas (none of 67) and uncommon in <em>BRAF</em><sup>V600E</sup> gliomas (one of 110) and histone mutant-driven gliomas (one of 150). In the paediatric age group (<18 years), primary MMRD was common in <em>IDH</em><sup>WT</sup> and <em>H3</em><sup>WT</sup> gliomas harbouring pathogenic <em>TP53</em> variants (21 of 61; 34·4%, 22·7–47·7) and in malignant <em>IDH</em><sup>mut</sup> gliomas (five of eight; 62·5%, 24·5–91·5). Germline aetiology accounted for 33 (94·3%) of 35 primary MMRD gliomas, including children, adolescents, and young adults with previously unrecognised Lynch syndrome. Survival was poor for patients with primary MMRD gliomas. Particularly poor survival was observed for those with <em>IDH</em><sup>mut</sup> astrocytomas with primary MMRD when compared with those with mismatch repair-proficient gliomas (HR 12·6, 95% CI 2·8–57·5; p=0·0011 by multivariable Cox regression). Immune checkpoint blockade was associated with improved survival for patients with primary MMRD gliomas compared with conventional chemoradiotherapy regimens (HR 0·4, 0·3–0·7; p=0·0017 by multivariable Cox regression), regardless of age or germline status.<h3>Interpretation</h3>Primary MMRD is more common than previously reported in gliomas in children, adolescents, and young adults, is enriched in specific molecular subgroups, and is associated with poor outcomes. Accurate detection, genetic testing, early diagnosis through sur
{"title":"The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study","authors":"Logine Negm, Jiil Chung, Liana Nobre, Julie Bennett, Nicholas R Fernandez, Nuno Miguel Nunes, Zhihui Amy Liu, Martin Komosa, Melyssa Aronson, Cindy Zhang, Lucie Stengs, Vanessa Bianchi, Melissa Edwards, Sheradan Doherty, Ayse Bahar Ercan, Maria F Cardenas, Michael Macias, Matthew R Lueder, Michelle Ku, Monique Johnson, Uri Tabori","doi":"10.1016/s1470-2045(24)00640-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00640-5","url":null,"abstract":"<h3>Background</h3>Gliomas are a major cause of cancer-related death among children, adolescents, and young adults (age 0–40 years). Primary mismatch repair deficiency (MMRD) is a pan-cancer mechanism with unique biology and therapeutic opportunities. We aimed to determine the extent and impact of primary MMRD in gliomas among children, adolescents, and young adults.<h3>Methods</h3>Clinical and molecular data were collected from a population-based cohort of children, adolescents, and young adults with gliomas from Toronto (TOR-Ped, age 0–18 years, collected Jan 1, 2000, to Dec 31, 2021; and TOR-AYA, age 18–40 years, collected Jan 1, 2000, to June 30, 2019). Additional validation paediatric cohorts from St Jude Children's Research Hospital (0–18 years, 2015–21) and the Children's Brain Tumor Network (0–18 years, 1981–2021) were used. Functional genomic tools were applied with the primary aim of assessing primary MMRD prevalence among glioma subgroups and germline impact. To evaluate the effect of primary MMRD on therapy and overall survival, Kaplan–Meier estimates were used on an additional cohort of patients with primary MMRD gliomas treated with immunotherapy.<h3>Findings</h3>1389 gliomas were included in the study. The prevalence of primary MMRD ranged between 3·7% and 12·4% in high-grade gliomas (overall 30 of 483; 6·2%, 95% CI 4·2–8·7) and less than 1% in low-grade gliomas (four of 899; 0·4%, 0·1–1·1; p<0·0001 by χ<sup>2</sup> test). Specific molecular analysis for all gliomas showed that primary MMRD was absent among oligodendrogliomas (none of 67) and uncommon in <em>BRAF</em><sup>V600E</sup> gliomas (one of 110) and histone mutant-driven gliomas (one of 150). In the paediatric age group (<18 years), primary MMRD was common in <em>IDH</em><sup>WT</sup> and <em>H3</em><sup>WT</sup> gliomas harbouring pathogenic <em>TP53</em> variants (21 of 61; 34·4%, 22·7–47·7) and in malignant <em>IDH</em><sup>mut</sup> gliomas (five of eight; 62·5%, 24·5–91·5). Germline aetiology accounted for 33 (94·3%) of 35 primary MMRD gliomas, including children, adolescents, and young adults with previously unrecognised Lynch syndrome. Survival was poor for patients with primary MMRD gliomas. Particularly poor survival was observed for those with <em>IDH</em><sup>mut</sup> astrocytomas with primary MMRD when compared with those with mismatch repair-proficient gliomas (HR 12·6, 95% CI 2·8–57·5; p=0·0011 by multivariable Cox regression). Immune checkpoint blockade was associated with improved survival for patients with primary MMRD gliomas compared with conventional chemoradiotherapy regimens (HR 0·4, 0·3–0·7; p=0·0017 by multivariable Cox regression), regardless of age or germline status.<h3>Interpretation</h3>Primary MMRD is more common than previously reported in gliomas in children, adolescents, and young adults, is enriched in specific molecular subgroups, and is associated with poor outcomes. Accurate detection, genetic testing, early diagnosis through sur","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-16DOI: 10.1016/s1470-2045(24)00405-4
Yannick Romero, Zuzanna Tittenbrun, Dario Trapani, Leslie Given, Karin Hohman, Mishka Kohli Cira, Kalina Duncan, Andre Ilbawi, Lisa M Stevens
Global efforts to highlight cancer and non-communicable diseases (NCDs) as a growing burden were first raised in 2005 World Health Assembly Resolution 58.22 and reinforced with Resolution 70.12 and the Global NCD action plan in 2017. One common thread for addressing cancer burden was the need to articulate cancer priorities within a comprehensive national cancer control plan (NCCP). Since 2012, the International Cancer Control Partnership provided guidance on cancer policy and planning, with the goal that every country should have an implementable plan. The purpose of the global review of NCCPs was to update global knowledge of the status and content of NCCPs. The global review included 16 new questions related to cancer equity, pandemic preparedness, global WHO initiatives, evidence-based recommendations, and other emerging trends. The findings can guide country-level decision makers on improvements to deliver person-centred cancer services to reduce the cancer burden.
{"title":"The changing global landscape of national cancer control plans","authors":"Yannick Romero, Zuzanna Tittenbrun, Dario Trapani, Leslie Given, Karin Hohman, Mishka Kohli Cira, Kalina Duncan, Andre Ilbawi, Lisa M Stevens","doi":"10.1016/s1470-2045(24)00405-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00405-4","url":null,"abstract":"Global efforts to highlight cancer and non-communicable diseases (NCDs) as a growing burden were first raised in 2005 World Health Assembly Resolution 58.22 and reinforced with Resolution 70.12 and the Global NCD action plan in 2017. One common thread for addressing cancer burden was the need to articulate cancer priorities within a comprehensive national cancer control plan (NCCP). Since 2012, the International Cancer Control Partnership provided guidance on cancer policy and planning, with the goal that every country should have an implementable plan. The purpose of the global review of NCCPs was to update global knowledge of the status and content of NCCPs. The global review included 16 new questions related to cancer equity, pandemic preparedness, global WHO initiatives, evidence-based recommendations, and other emerging trends. The findings can guide country-level decision makers on improvements to deliver person-centred cancer services to reduce the cancer burden.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"134 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142832311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-12DOI: 10.1016/s1470-2045(24)00598-9
Anna Santarsieri, Emily Mitchell, My H Pham, Rashesh Sanghvi, Janina Jablonski, Henry Lee-Six, Katherine Sturgess, Pauline Brice, Tobias F Menne, Wendy Osborne, Thomas Creasey, Kirit M Ardeshna, Joanna Baxter, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh D Chavda, Graham P Collins, Dominic J Culligan, Kate Cwynarski, George A Follows
<h3>Background</h3>Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin–etoposide–doxorubicin–cyclophosphamide–vincristine–procarbazine–prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this drug substitution on the mutation burden in stem cells, patient survival, and toxicity.<h3>Methods</h3>In this two-part retrospective, observational study, we first compared mutational landscapes in haematopoietic stem and progenitor cells (HSPCs) from patients with advanced-stage Hodgkin lymphoma in remission for at least 6 months who had been treated with eBEACOPDac (eBEACOPDac cohort), eBEACOPP (real-world eBEACOPP cohort), or doxorubicin–bleomycin–vinblastine–dacarbazine (ABVD); in buccal DNA from five children of a female patient with classical Hodgkin lymphoma treated with eBEACOPP before conceiving the third child; in sperm DNA from a patient with mild oligospermia treated with eBEACOPP; and in caecal adenocarcinoma and healthy colon tissue from a survivor of Hodgkin lymphoma treated with chlorambucil–vinblastine–procarbazine–prednisolone. For the second part, we analysed efficacy and toxicity data from adult patients (aged >16 years) treated with first-line eBEACOPDac (eBEACOPDac cohort) at 25 centres across UK, Ireland, and France; efficacy was compared with the German HD18 eBEACOPP trial data and toxicity with a UK real-world dataset. Participants in the German HD18 and UK real-world datasets were adults (aged >16 years) with previously untreated Hodgkin lymphoma, treated with first-line eBEACOPP. We had two co-primary objectives: to define the comparative stem-cell mutation burden and mutational signatures after treatment with or without procarbazine-containing chemotherapy (first study part); and to determine progression-free survival of patients with Hodgkin lymphoma treated with eBEACOPP or eBEACOPDac (second study part). Secondary objectives included overall survival and explored differences in specific toxicity outcomes, including transfusion requirements and measures of reproductive health (second study part).<h3>Findings</h3>In the first part of the study (mutational analysis), patients treated with eBEACOPP (n=5) exhibited a higher burden of point mutations in HSPCs compared with those treated with eBEACOPDac (n=4) or ABVD (n=3; excess mutations 1150 [95% CI 934–1366] <em>vs</em> 290 [241–339] <em>vs</em> 186 [116–254]). Two novel mutational signatures, SBSA (SBS25-like) and SBSB, were identified in HSPCs and in a single neoplastic and healthy colon sample from patients who received procarbazine-containing chemotherapy. SBSB was also identified in germline DNA of three children conceived after eBEACOPP and in sperm of a male patient treated with eBEACOPP. SBSC was detected in patients treated with either AB
{"title":"The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study","authors":"Anna Santarsieri, Emily Mitchell, My H Pham, Rashesh Sanghvi, Janina Jablonski, Henry Lee-Six, Katherine Sturgess, Pauline Brice, Tobias F Menne, Wendy Osborne, Thomas Creasey, Kirit M Ardeshna, Joanna Baxter, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh D Chavda, Graham P Collins, Dominic J Culligan, Kate Cwynarski, George A Follows","doi":"10.1016/s1470-2045(24)00598-9","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00598-9","url":null,"abstract":"<h3>Background</h3>Procarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin–etoposide–doxorubicin–cyclophosphamide–vincristine–procarbazine–prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact of this drug substitution on the mutation burden in stem cells, patient survival, and toxicity.<h3>Methods</h3>In this two-part retrospective, observational study, we first compared mutational landscapes in haematopoietic stem and progenitor cells (HSPCs) from patients with advanced-stage Hodgkin lymphoma in remission for at least 6 months who had been treated with eBEACOPDac (eBEACOPDac cohort), eBEACOPP (real-world eBEACOPP cohort), or doxorubicin–bleomycin–vinblastine–dacarbazine (ABVD); in buccal DNA from five children of a female patient with classical Hodgkin lymphoma treated with eBEACOPP before conceiving the third child; in sperm DNA from a patient with mild oligospermia treated with eBEACOPP; and in caecal adenocarcinoma and healthy colon tissue from a survivor of Hodgkin lymphoma treated with chlorambucil–vinblastine–procarbazine–prednisolone. For the second part, we analysed efficacy and toxicity data from adult patients (aged >16 years) treated with first-line eBEACOPDac (eBEACOPDac cohort) at 25 centres across UK, Ireland, and France; efficacy was compared with the German HD18 eBEACOPP trial data and toxicity with a UK real-world dataset. Participants in the German HD18 and UK real-world datasets were adults (aged >16 years) with previously untreated Hodgkin lymphoma, treated with first-line eBEACOPP. We had two co-primary objectives: to define the comparative stem-cell mutation burden and mutational signatures after treatment with or without procarbazine-containing chemotherapy (first study part); and to determine progression-free survival of patients with Hodgkin lymphoma treated with eBEACOPP or eBEACOPDac (second study part). Secondary objectives included overall survival and explored differences in specific toxicity outcomes, including transfusion requirements and measures of reproductive health (second study part).<h3>Findings</h3>In the first part of the study (mutational analysis), patients treated with eBEACOPP (n=5) exhibited a higher burden of point mutations in HSPCs compared with those treated with eBEACOPDac (n=4) or ABVD (n=3; excess mutations 1150 [95% CI 934–1366] <em>vs</em> 290 [241–339] <em>vs</em> 186 [116–254]). Two novel mutational signatures, SBSA (SBS25-like) and SBSB, were identified in HSPCs and in a single neoplastic and healthy colon sample from patients who received procarbazine-containing chemotherapy. SBSB was also identified in germline DNA of three children conceived after eBEACOPP and in sperm of a male patient treated with eBEACOPP. SBSC was detected in patients treated with either AB","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<h3>Background</h3>Previous studies have shown that colorectal cancer incidence is increasing among younger adults (aged <50 years) in multiple high-income western countries in contrast with stabilising or decreasing trends in incidence in older adults (aged ≥50 years). This study aimed to investigate contemporary colorectal cancer incidence trends in younger adults versus older adults.<h3>Methods</h3>Colorectal cancer incidence data, including year of diagnosis, sex, and 5-year age group for 50 countries and territories, were extracted from the WHO–International Agency for Research on Cancer Cancer Incidence in Five Continents Plus database. The Human Development Index 2022 was retrieved from the United Nations Development Programme and grouped into very high (>0·80), high (0·70–0·79), medium (0·55–0·69), and low (<0·55) categories. Age-standardised incidence rates (ASR) per 100 000 person-years of early-onset (diagnosed between ages 25 to 49 years) and late-onset (diagnosed between ages 50 to 74 years) colorectal cancer (ICD 10th revision, C18–20), diagnosed between 1943–2003 and 2015–17, were calculated using the direct method and Segi–Doll world standard population). The primary study objective was to examine contemporary colorectal cancer incidence trends in younger adults versus older adults using data until 2017 from 50 countries and territories. Temporal trends were visualised and quantified with joinpoint regression, stratified by age at diagnosis (25–49 years or 50–74 years). Average annual percentage changes (AAPC) were estimated.<h3>Findings</h3>In the most recent 5 years (2013–17 for all countries analysed, except for Japan [2011–15], Spain [2012–16], and Costa Rica [2012–16]), the incidence rate of early-onset colorectal cancer was highest in Australia (ASR 16·5 [95% CI 16·1–16·9]), the USA (Puerto Rico; 15·2 [14·2–16·2]), New Zealand (14·8 [14·0–15·6]), the USA (14·8 [14·7–14·9]), and South Korea (14·3 [14·0–14·5]) and lowest in Uganda (4·4 [3·6–5·2]) and India (3·5 [3·3–3·7]). The highest incidence rates among older adults were found in the Netherlands (168·4 [166·9–170·0]) and Denmark (158·3 [155·8–160·9]) and the lowest were in Uganda (45·9 [38·5–51·4]) and India (23·5 [22·8–24·3]). In terms of AAPC, in the most recent 10 years, incidence rates of early-onset colorectal cancer were stable in 23 countries, but increased in 27 countries with the greatest annual increases in New Zealand (AAPC 3·97% [95% CI 2·44–5·52]), Chile (3·96% [1·26–6·74]), Puerto Rico (3·81% [2·68–4·96]), and England (3·59% [3·12–4·06]). 14 of the 27 countries and territories showed either stable (Argentina, France, Ireland, Norway, and Puerto Rico) or decreasing (Australia, Canada, Germany, Israel, New Zealand, Slovenia, England, Scotland, and the USA) trends in older adults. For the 13 countries with increasing trends in both age groups, the average annual percentage increase in younger compared to older adults was higher in Chile, Japan, Sweden, t
{"title":"Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data","authors":"Hyuna Sung, Rebecca L Siegel, Mathieu Laversanne, Chenxi Jiang, Eileen Morgan, Mariam Zahwe, Yin Cao, Freddie Bray, Ahmedin Jemal","doi":"10.1016/s1470-2045(24)00600-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00600-4","url":null,"abstract":"<h3>Background</h3>Previous studies have shown that colorectal cancer incidence is increasing among younger adults (aged <50 years) in multiple high-income western countries in contrast with stabilising or decreasing trends in incidence in older adults (aged ≥50 years). This study aimed to investigate contemporary colorectal cancer incidence trends in younger adults versus older adults.<h3>Methods</h3>Colorectal cancer incidence data, including year of diagnosis, sex, and 5-year age group for 50 countries and territories, were extracted from the WHO–International Agency for Research on Cancer Cancer Incidence in Five Continents Plus database. The Human Development Index 2022 was retrieved from the United Nations Development Programme and grouped into very high (>0·80), high (0·70–0·79), medium (0·55–0·69), and low (<0·55) categories. Age-standardised incidence rates (ASR) per 100 000 person-years of early-onset (diagnosed between ages 25 to 49 years) and late-onset (diagnosed between ages 50 to 74 years) colorectal cancer (ICD 10th revision, C18–20), diagnosed between 1943–2003 and 2015–17, were calculated using the direct method and Segi–Doll world standard population). The primary study objective was to examine contemporary colorectal cancer incidence trends in younger adults versus older adults using data until 2017 from 50 countries and territories. Temporal trends were visualised and quantified with joinpoint regression, stratified by age at diagnosis (25–49 years or 50–74 years). Average annual percentage changes (AAPC) were estimated.<h3>Findings</h3>In the most recent 5 years (2013–17 for all countries analysed, except for Japan [2011–15], Spain [2012–16], and Costa Rica [2012–16]), the incidence rate of early-onset colorectal cancer was highest in Australia (ASR 16·5 [95% CI 16·1–16·9]), the USA (Puerto Rico; 15·2 [14·2–16·2]), New Zealand (14·8 [14·0–15·6]), the USA (14·8 [14·7–14·9]), and South Korea (14·3 [14·0–14·5]) and lowest in Uganda (4·4 [3·6–5·2]) and India (3·5 [3·3–3·7]). The highest incidence rates among older adults were found in the Netherlands (168·4 [166·9–170·0]) and Denmark (158·3 [155·8–160·9]) and the lowest were in Uganda (45·9 [38·5–51·4]) and India (23·5 [22·8–24·3]). In terms of AAPC, in the most recent 10 years, incidence rates of early-onset colorectal cancer were stable in 23 countries, but increased in 27 countries with the greatest annual increases in New Zealand (AAPC 3·97% [95% CI 2·44–5·52]), Chile (3·96% [1·26–6·74]), Puerto Rico (3·81% [2·68–4·96]), and England (3·59% [3·12–4·06]). 14 of the 27 countries and territories showed either stable (Argentina, France, Ireland, Norway, and Puerto Rico) or decreasing (Australia, Canada, Germany, Israel, New Zealand, Slovenia, England, Scotland, and the USA) trends in older adults. For the 13 countries with increasing trends in both age groups, the average annual percentage increase in younger compared to older adults was higher in Chile, Japan, Sweden, t","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"232 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142809626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-12DOI: 10.1016/s1470-2045(24)00718-6
Sharmila Devi
No Abstract
{"title":"Pharmacy closures in the USA and Europe","authors":"Sharmila Devi","doi":"10.1016/s1470-2045(24)00718-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00718-6","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142820867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-12DOI: 10.1016/s1470-2045(24)00719-8
Karl Gruber
No Abstract
无摘要
{"title":"Prior authorisation is can harm patients with cancer in the USA","authors":"Karl Gruber","doi":"10.1016/s1470-2045(24)00719-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00719-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142816144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：